Trevi Therapeutics ( Trevi Therapeutics)

Primary tabs

Trevi Therapeutics's picture

Management

Contact Address

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions.

Trevi Therapeutics press release, blog etc

Mon, 03/10/2025 - 06:21 Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Sun, 03/09/2025 - 17:22 Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Tue, 02/25/2025 - 17:51 Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Fri, 02/16/2024 - 06:21 Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Tue, 11/15/2022 - 20:31 Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference
Sun, 11/13/2022 - 22:52 Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer
Thu, 11/03/2022 - 11:54 Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022
Thu, 10/27/2022 - 10:27 Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting
Fri, 09/23/2022 - 13:59 Trevi Therapeutics Announces Pricing of $55 Million Public Offering
Wed, 09/21/2022 - 23:06 Trevi Therapeutics Announces Proposed Public Offering
Mon, 09/19/2022 - 09:28 Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Mon, 09/19/2022 - 09:25 Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022
Mon, 09/12/2022 - 11:57 Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Mon, 08/08/2022 - 21:30 Trevi Therapeutics to Present at Upcoming August Conferences
Thu, 08/04/2022 - 16:23 Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
Thu, 07/07/2022 - 13:03 Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS)
Wed, 06/29/2022 - 02:20 Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio in the Treatment of Prurigo Nodularis
Tue, 06/07/2022 - 08:32 Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention
more

InfoBox

HomePagewww.trevitherapeutics.com
Facebookwww.facebook.com/trevitherapeutics
Twittertwitter.com/TreviThera
LinkedInwww.linkedin.com/company/2073467?trk=pro_other_cmpy